Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from AuMake Ltd. ( (AU:XEN) ) is now available.
Xenitra Limited reported a more than 300% jump in preliminary unaudited Q3 sales to $8.3 million versus Q2, driven primarily by its Nutritionals division and underpinned by a $30 million strategic offtake partnership with Rockcheck Group for Danone products. Management said March sales surpassed $4 million, effectively restoring annualised revenue to FY24 levels after a restructuring year, while newly launched higher-margin OTC medicines and blockchain tokenised sales channels are expected to begin contributing in Q4, positioning the company for multi-market growth on a leaner cost base and deeper distribution ties with Rockcheck.
The company highlighted that its revamped structure has delivered strong sales momentum while laying foundations for future growth across new markets aligned with its core strengths in sales and marketing. The acquisition of Fukang has provided an established team and online footprint for the OTC medicines division, and the launch of the OPAL token has initiated Xenitra’s Web3, real-world-asset-backed tokenised sales ecosystem, which the board views as a key innovation for unlocking higher-margin revenue streams through its existing distribution network.
More about AuMake Ltd.
Xenitra Limited is an Asia-focused distributor of fast-moving consumer goods, nutraceuticals, OTC medicines and personal care products, using a blockchain tokenised sales ecosystem. Its products are sold through B2B wholesale, retail distribution and major ecommerce platforms, with more than $70 million in sales recorded since 2024.
Current Market Cap: A$11.59M
For a thorough assessment of XEN stock, go to TipRanks’ Stock Analysis page.